



Supplemental figure 5: Molecular characterization of exosomes derived from TPC1, FTC-133, and 8505C using Western blot analysis. **(A)** Purified exosomes secreted by three thyroid cancer cell lines were analyzed by immunoblotting for the presence of the exosome marker CD63. **(B)** CD63 expression in exosomes secreted by equal amount of thyroid cancer cells treated with Brefeldin A, or vehicle (Methanol) (12 hours for TPC1 and FTC-133 and 16 hours for 8505C). **(C)** expression of miR-145 was decreased by the treatment of thyroid cancer cells with GW4869 (1 μ M) during 48h. **(D)** Purified exosomes secreted by equal amount of cells treated with GW4869 or vehicle (DMSO) during 48 hours were analyzed by Western blot for CD63 expression. (*, $p < 0.05$; **, $p < 0.01$, *** $p < 0.001$).